Granted Patent
B2
US 12,378,319 · App. 17/564,022 · Granted Aug 5, 2025
Anti-CD137 molecules and use thereof
Inventors:
Peter Peizhi Luo (Suzhou, CN); Fangyong Du (Suzhou, CN); Yan Li (Suzhou, CN); Guizhong Liu (Suzhou, CN); Jun Chen (Suzhou, CN); Xiaohong She (Suzhou, CN); Peter Cheung (Suzhou, CN)
Assignee:
Adagene Inc.
C07K16/2878A61K39/001102A61K39/3955A61P35/00C07K16/2818A61K2039/505A61K45/06C07K2317/33C07K2317/52C07K2317/55C07K2317/56C07K2317/75C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
Claims (16)
1. A polynucleotide encoding an antibody, or antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment thereof binds to an extracellular domain of human CD137, and comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an HVR-H1, an HVR-H2, and an HVR-H3, the light chain variable region comprises an HVR-L1, an HVR-L2, and an HVR-L3, and wherein:
(1) the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 731, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 755, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 779, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 803, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 827, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 851;
(2) the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 711, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 735, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 759, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 783, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 807, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 831; or
(3) the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 712, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 736, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 760, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 784, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 808, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 832.
2. A vector comprising the polynucleotide of claim 1 .
3. The vector of claim 2 , wherein the vector is an expression vector.
4. A host cell comprising the vector of claim 2 .
5. The polynucleotide of claim 1 , wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 711, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 735, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 759, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 783, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 807, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 831.
6. The polynucleotide of claim 5 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 41, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 42.
7. The polynucleotide of claim 6 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 617, and the light chain comprises the amino acid sequence of SEQ ID NO: 618.
8. The polynucleotide of claim 1 , wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 731, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 755, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 779, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 803, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 827, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 851.
9. The polynucleotide of claim 8 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 72.
10. The polynucleotide of claim 9 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 657, and the light chain comprises the amino acid sequence of SEQ ID NO: 658.
11. The polynucleotide of claim 1 , wherein the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 712, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 736, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 760, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 784, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 808, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 832.
12. The polynucleotide of claim 11 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 61, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 62.
13. The polynucleotide of claim 12 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 619, and the light chain comprises the amino acid sequence of SEQ ID NO: 620.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 23, 2023
From: LUO, PETER PEIZHI; DU, FANGYONG; LI, YAN; LIU, GUIZHONG; CHEN, JUN; SHE, XIAOHONG; CHEUNG, PETER
To: ADAGENE INC.
Reel/Frame 063733/0102 →
Continuity (3)
Continuation In Part
PCTCN2017098332
· Aug 21, 2017
References Cited (344)
US 4399216A
· Axel et al.
· 1983
[cited by applicant]
US 4634665A
· Axel et al.
· 1987
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5179017A
· Axel et al.
· 1993
[cited by applicant]
US 5648237A
· Carter
· 1997
[cited by applicant]
US 5677425A
· Axel et al.
· 1997
[cited by applicant]
US 5789199A
· Joly et al.
· 1998
[cited by applicant]
US 5840523A
· Simmons et al.
· 1998
[cited by applicant]
US 5959177A
· Hein et al.
· 1999
[cited by applicant]
US 5994619A
· Axel et al.
· 1999
[cited by applicant]
US 6040498A
· Stomp et al.
· 2000
[cited by applicant]
US 6172197B1
· Axel et al.
· 2001
[cited by applicant]
US 6207156B1
· Kuchroo et al.
· 2001
[cited by applicant]
US 6291158B1
· Bodmer et al.
· 2001
[cited by applicant]
US 6417429B1
· Hein et al.
· 2002
[cited by applicant]
US 6420548B1
· Vezina et al.
· 2002
[cited by applicant]
US 6582915B1
· Stice et al.
· 2003
[cited by applicant]
US 6593081B1
· McCafferty et al.
· 2003
[cited by applicant]
US 6696245B2
· Winter et al.
· 2004
[cited by applicant]
US 6765087B1
· Casterman et al.
· 2004
[cited by applicant]
US 6838254B1
· Hamers et al.
· 2005
[cited by applicant]
US 6887673B2
· Kunkel et al.
· 2005
[cited by applicant]
US 6933365B2
· Kumagai et al.
· 2005
[cited by applicant]
US 6933368B2
· Co et al.
· 2005
[cited by applicant]
US 7125978B1
· Vezina et al.
· 2006
[cited by applicant]
US 7138500B1
· Goodwin et al.
· 2006
[cited by applicant]
US 7214493B2
· Kunkel et al.
· 2007
[cited by applicant]
US 7288638B2
· Jure-Kunkel et al.
· 2007
[cited by applicant]
US 7659384B2
· Jure-Kunkel et al.
· 2010
[cited by applicant]
US 7879984B2
· Martin et al.
· 2011
[cited by applicant]
US 8017114B2
· Korman et al.
· 2011
[cited by applicant]
US 8119129B2
· Jure-Kunkel et al.
· 2012
[cited by applicant]
US 8137667B2
· Jure-Kunkel et al.
· 2012
[cited by applicant]
US 8337850B2
· Ahrens et al.
· 2012
[cited by applicant]
US 8716452B2
· Jure-Kunkel et al.
· 2014
[cited by applicant]
US 8821867B2
· Ahrens et al.
· 2014
[cited by applicant]
US 9382328B2
· Jure-Kunkel et al.
· 2016
[cited by applicant]
US 9468678B2
· Ahrens et al.
· 2016
[cited by applicant]
US 20030118588A1
· Diehl et al.
· 2003
[cited by applicant]
US 20030232347A1
· Anderson et al.
· 2003
[cited by applicant]
US 20060153808A1
· Cristofanilli et al.
· 2006
[cited by applicant]
US 20080305113A1
· Kwon et al.
· 2008
[cited by applicant]
US 20100189651A1
· Stagliano et al.
· 2010
[cited by applicant]
US 20110059045A1
· Bermejo et al.
· 2011
[cited by applicant]
US 20120076722A1
· Strome et al.
· 2012
[cited by applicant]
US 20160145604A1
· Du et al.
· 2016
[cited by applicant]
US 20160368998A1
· Jure-Kunkel et al.
· 2016
[cited by applicant]
US 20190241886A1
· Du et al.
· 2019
[cited by applicant]
US 20200017594A9
· Al-Shamkhani et al.
· 2020
[cited by applicant]
US 20200377608A1
· Luo et al.
· 2020
[cited by applicant]
US 20220089757A1
· Luo et al.
· 2022
[cited by applicant]
US 20230133118A1
· Luo et al.
· 2023
[cited by applicant]
US 20230242663A1
· Luo et al.
· 2023
[cited by applicant]
US 20230287597A1
· Luo et al.
· 2023
[cited by applicant]
US 20240150749A1
· Luo et al.
· 2024
[cited by applicant]
AU 2013202755A1
· 2013
[cited by applicant]
AU 2015201981A1
· 2015
[cited by applicant]
CN 1357009A
· 2002
[cited by applicant]
CN 1749270A
· 2006
[cited by applicant]
CN 1867585A
· 2006
[cited by examiner]
CN 1867585B
· 2011
[cited by examiner]
CN 102482347A
· 2012
[cited by applicant]
CN 105296433A
· 2016
[cited by applicant]
CN 106163556A
· 2016
[cited by applicant]
CN 107840887A
· 2018
[cited by applicant]
CN 109963873A
· 2019
[cited by applicant]
CN 110546166A
· 2019
[cited by applicant]
CN 111465615A
· 2020
[cited by applicant]
CN 111511762A
· 2020
[cited by applicant]
CN 119137159A
· 2024
[cited by applicant]
EP 368684B1
· 1994
[cited by applicant]
EP 338841B1
· 1995
[cited by applicant]
EP 616640B1
· 2004
[cited by applicant]
EP 2161336A1
· 2010
[cited by applicant]
KR 20060126455A
· 2006
[cited by applicant]
KR 20130079533A
· 2013
[cited by applicant]
KR 20170036092A
· 2017
[cited by applicant]
WO WO1987004462A1
· 1987
[cited by applicant]
WO WO1989001036A1
· 1989
[cited by applicant]
WO WO1996032495A1
· 1996
[cited by applicant]
WO WO1998042752A1
· 1998
[cited by applicant]
WO WO2000029445A1
· 2000
[cited by applicant]
WO WO2000037504A2
· 2000
[cited by applicant]
WO WO2001014424A2
· 2001
[cited by applicant]
WO WO2002053596A2
· 2002
[cited by applicant]
WO WO2002055106A2
· 2002
[cited by applicant]
WO WO2003002609A2
· 2003
[cited by applicant]
WO WO2003015711A2
· 2003
[cited by applicant]
WO WO2003040170A2
· 2003
[cited by applicant]
WO WO2003048731A2
· 2003
[cited by applicant]
WO WO2003074678A2
· 2003
[cited by applicant]
WO WO2004003019A3
· 2004
[cited by applicant]
WO WO2004010947A2
· 2004
[cited by applicant]
WO WO2004016805A2
· 2004
[cited by applicant]
WO WO2004035607A2
· 2004
[cited by applicant]
WO WO2004056312A2
· 2004
[cited by applicant]
WO WO2004058821A2
· 2004
[cited by applicant]
WO WO2004081026A2
· 2004
[cited by applicant]
WO WO2004101790A1
· 2004
[cited by applicant]
WO WO2005035572A2
· 2005
[cited by applicant]
WO WO2005035584A1
· 2005
[cited by applicant]
WO WO2005044859A2
· 2005
[cited by applicant]
WO WO2005103081A2
· 2005
[cited by applicant]
WO WO2005120568A1
· 2005
[cited by applicant]
WO WO2006029220A2
· 2006
[cited by applicant]
WO WO2006066568A2
· 2006
[cited by applicant]
WO WO2006079372A1
· 2006
[cited by applicant]
WO WO2006088447A1
· 2006
[cited by applicant]
WO WO2006129163A1
· 2006
[cited by applicant]
WO WO2007031875A2
· 2007
[cited by applicant]
WO WO2007059782A1
· 2007
[cited by applicant]
WO WO2009022215A1
· 2009
[cited by applicant]
WO WO2009025846A2
· 2009
[cited by applicant]
WO WO2009079335A1
· 2009
[cited by applicant]
WO WO2010081173A2
· 2010
[cited by applicant]
WO WO2012065086A1
· 2012
[cited by applicant]
WO WO2013192550A2
· 2013
[cited by applicant]
WO WO2015094123A1
· 2015
[cited by applicant]
WO WO2015095410A1
· 2015
[cited by applicant]
WO WO2015125159A1
· 2015
[cited by applicant]
WO WO2015156268A1
· 2015
[cited by applicant]
WO WO2016014974A1
· 2016
[cited by applicant]
WO WO2016115275A1
· 2016
[cited by applicant]
WO WO2016130898A2
· 2016
[cited by applicant]
WO WO2016130986A1
· 2016
[cited by applicant]
WO WO2016134358A1
· 2016
[cited by applicant]
WO WO2016149201A2
· 2016
[cited by applicant]
WO WO2016179285A1
· 2016
[cited by applicant]
WO WO2016179335A1
· 2016
[cited by applicant]
WO WO2016185016A1
· 2016
[cited by applicant]
WO WO2016200645A1
· 2016
[cited by applicant]
WO WO2017011580A3
· 2017
[cited by applicant]
WO WO2017049452A1
· 2017
[cited by applicant]
WO WO2017077085A2
· 2017
[cited by applicant]
WO WO2017106372A1
· 2017
[cited by applicant]
WO WO2017106656A1
· 2017
[cited by applicant]
WO WO2017112811A1
· 2017
[cited by applicant]
WO WO2017140826A1
· 2017
[cited by applicant]
WO WO2017151940A2
· 2017
[cited by applicant]
WO WO2017194265A1
· 2017
[cited by applicant]
WO WO2017205745A1
· 2017
[cited by applicant]
WO WO2018091740A2
· 2018
[cited by applicant]
WO WO2018127787A1
· 2018
[cited by applicant]
WO WO2018191502A2
· 2018
[cited by applicant]
WO WO2018199595A1
· 2018
[cited by applicant]
WO WO2018202649A1
· 2018
[cited by applicant]
WO WO2018209701A1
· 2018
[cited by applicant]
WO WO2019014328A2
· 2019
[cited by applicant]
WO WO2019020774A2
· 2019
[cited by applicant]
WO WO2019036842A1
· 2019
[cited by applicant]
WO WO2019036855A1
· 2019
[cited by applicant]
WO WO2019036856A1
· 2019
[cited by applicant]
WO WO2019037711A1
· 2019
[cited by applicant]
WO WO2019089753A2
· 2019
[cited by applicant]
WO WO2019104716A1
· 2019
[cited by applicant]
WO WO2019105468A1
· 2019
[cited by applicant]
WO WO2019148445A1
· 2019
[cited by applicant]
WO WO2019149281A1
· 2019
[cited by applicant]
WO WO2019149282A1
· 2019
[cited by applicant]
WO WO2020244574A1
· 2020
[cited by applicant]
WO WO2022170740A1
· 2022
[cited by applicant]
Paul. Fundamental Immunology, 3rd Edition, Raven Press, New York, Chapter 8, pp. 292-295, 1993 (Year: 1993).
[cited by examiner]
MacCallum et al. Antibody-antigen Interactions: Contact Analysis and Binding Site Topography. Journal of Molecular Biology, 262:732-745, 1996 (Year: 1996).
[cited by examiner]
Casset et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 307:198-205, 2003 (Year: 2003).
[cited by examiner]
Vajdos et al. Comprehensive Functional Maps of the Antigenbinding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis. Journal of Molecular Biology, Jul. 5, 2002;320(2):415-28 (Year: 2003).
[cited by examiner]
Sela-Culang et al. 2013. The structural basis of antibody-antigen recognition; Frontiers in Immunology 4(302):1-13 (Year: 2013).
[cited by examiner]
Makkouk et al., (2016). “Rationale for anti-CD137 cancer immunotherapy,” Eur J Cancer, 54:112-119. Abstract Only.
[cited by applicant]
Sanchez-Paulete et al., (2016). “Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy,” Eur J Immunol., 46(3):513-22.
[cited by applicant]
U.S. Appl. No. 18/153,221, filed Jan. 11, 2023, titled “Activatable Antibodies and Methods of Making and Using Thereof,” (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii).
[cited by applicant]
Bird et al., (1988). “Single-chain antigen-binding proteins,” Science, 242(4877):423-426.
[cited by applicant]
Broll, (2001). “CD137 Expression in Tumor Vessel Walls: High Correlation With Malignant Tumors,” Amer. J. Clin. Pathol., 115(4):543-549.
[cited by applicant]
Casset et al., (2003). “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochemical and Biophysical Research Communications, 307:198-205.
[cited by applicant]
Cheuk et al., (2004). “Role of 4-1BB:4-1BB ligand in cancer immunotherapy,” Cancer Gene Therapy, 11(3): 215-226.
[cited by applicant]
Chin et al., (2018). “Structure of the 4-1 BB/4-1 Bbl complex and distinct binding and functional properties of utomilumab and urelumab,” Nat Commun., 9:4679, 13 pages.
[cited by applicant]
ClinicalTrials.org, (2019). “Adagene (Suzhou) Limited, NCT03802955: Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma,” Available online at <https:/ /clinicaltrials.gov/ct2/show/NCT038…
[cited by applicant]
Committee for Medicinal Products for Human Use (CHMP). Assessment Report for Yervoy (ipilirnumab). CHMP assessment report EMNCHMP/557664/2011. May 19, 2011(May 19, 2011) pp. 1-71.
[cited by applicant]
Croft, (2009). “The role of TNF superfamily members in T-cell function and diseases,” Nat Rev Immunol., 9:271-285.
[cited by applicant]
Drenkard, (2007). “CD137 is expressed on blood vessel walls at sites of Inflammation and enhances monocyte migratory activity,” FASEB Journal, 21: 456-463.
[cited by applicant]
Extended European Sear Report and Opinion for European Patent Application No. 18847500.8, mailed on Apr. 22, 2021, 8 pages.
[cited by applicant]
Extended European Sear Report and Opinion for European Patent Application No. 18883687.8, mailed on Jul. 30, 2021, 10 pages.
[cited by applicant]
Feldhaus et al., (2003). “Flow-cytometric isolation of human antibodies from a non-immune
[cited by applicant]
Ferrara et al., (2015). “Recombinant renewable polyclonal antibodies,” mABs, 7(1):32-41.
[cited by applicant]
Ferrara et al., (2018). “Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers-Letter,” Clin. Cancer Res, 25(11):3468.
[cited by applicant]
GenBank Accession No. AAH06196.1, “Tumor necrosis factor receptor superfamily, member 9 [
[cited by applicant]
GenBank Accession No. ABY47575.1, “CD137 [Macaca fascicularis],” Dec. 5, 2008, Available at: < https://www.ncbi.nlm.nih.gov/protein/ABY47575.1>, 2 pages.
[cited by applicant]
Gerspach et al., (2006). “Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface,” Cancer Immunol Immunother, 55(12):1590-1600.
[cited by applicant]
Guinn et al., (1999). “4-1BBL Cooperates With B7-1 and B7-2 in Converting a B Cell Lymphoma Cell Line Into a Long-Lasting Antitumor Vaccine,” J. Immunol., 162(8):5003-10.
[cited by applicant]
Ha et al., (2019). “Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody,” PNAS, 116(2):609-618.
[cited by applicant]
He et al., (2017). “Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies,” Oncotarget 8:67129-67139.
[cited by applicant]
Hurwitz et al., (1998). “CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma,” Proc Natl Acad Sci USA 95 (17):10067-71.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Apr. 28, 2019, issued for PCT/CN2019/074580, filed Feb. 2, 2019, 15 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Aug. 18, 2021, issued for PCT/CN2021/093511, filed May 13, 2021, 15 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Feb. 18, 2021, issued for PCT/CN2020/094278, filed Jun. 4, 2020, 17 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Feb. 27, 2019, issued for PCT/CN2018/118631, filed Nov. 30, 2018, 15 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Jan. 27, 2021, issued for PCT/CN2020/090073, filed May 13, 2020, 16 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Jan. 27, 2021, issued for PCT/CN2020/115795, filed Sep. 17, 2020, 14 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed May 25, 2018, issued for PCT/CN2017/098332, filed Aug. 21, 2017, 20 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed May 8, 2019, issued for PCT/CN2019/074581, filed Feb. 2, 2019, 13 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Nov. 14, 2018, issued for PCT/CN2018/101501, filed Aug. 21, 2018, 12 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Nov. 6, 2018, issued for PCT/CN2018/075065, filed Feb. 2, 2018, 16 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Nov. 7, 2018, issued for PCT/CN2018/075064, filed Feb. 2, 2018, 17 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Sep. 4, 2020, issued for PCT/CN2020/094371, filed Jun. 4, 2020, 14 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Sep. 7, 2018, issued for PCT/CN2017/0114247, filed Dec. 1, 2017, 14 pages.
[cited by applicant]
Jiang et al., (2004). “Tumor imaging by means of proteolytic activation of cell-penetrating peptides,” Proc Natl Acad Sci USA 101(51):17867-72.
[cited by applicant]
Ke et al., (1997). “Optimal Subsite Occupancy and Design of a Selective Inhibitor of Urokinase,” J Biol Chem 272(33):20456-62.
[cited by applicant]
Keler et al., (2003). “Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus,” The Journal of Immunology, 171:6251-59.
[cited by applicant]
Kwon et al., (1997). “Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer,” Proc Natl Acad Sci USA, 94(15):8099-103.
[cited by applicant]
Labiano et al., (2016). “Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism,” Oncoimmunology, 5:e1062967, 10 pages.
[cited by applicant]
Lee et al., (2016). “Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy,” Nat Commun 7(13354):1-10.
[cited by applicant]
Lei et al., (1987). “Characterization of the Erwinia carotovora pelB gene and its product pectate lyase,” J. Bacteriol., 169:4379-83.
[cited by applicant]
Li (2014). “Expression of human CD137 and CD28 proteins and preparation of their specific monoclonal antibodies,” Chinese Master's Theses Full-Text Database Medicine and Health Sciences 2:E059-133; pp. 1-73. English Abs…
[cited by applicant]
Li et al., (2013). “Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137,” Clin Pharmacol., 5(1):47-53.
[cited by applicant]
Lynch (2008). “The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer,” Immunol Rev., 222(1):277-286.
[cited by applicant]
MacCallum et al., (1996). “Antibody-antigen interactions: contact analysis and binding site topography,” Journal of Molecular Biology, 262:732-745.
[cited by applicant]
Martinet et al., (2000). “Immunomodulatory Gene Therapy With Interleukin 12 and 4-1BB Ligand: Long-Term Remission of Liver Metastases in a Mouse Model,” J Natl Cancer Inst., 92(11):931-6.
[cited by applicant]
Martinez-Forero et al., (2013). “T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes,” J Immunol., 190(12):6694-706.
[cited by applicant]
Melero et al., (1998). “Amplification of Tumor Immunity by Gene Transfer of the Co-Stimulatory 4-1BB Ligand: Synergy With the CD28 Co-Stimulatory Pathway,” Eur. J. Immunol., 28(3):1116-21.
[cited by applicant]
Narazaki et al., (2010). “CD137 agonist antibody prevents cancer 1-50 recurrence: contribution of CD 13 7 on both hematopoietic and nonhematopoietic cells,” Immunobiology. 10(115):1941-1948.
[cited by applicant]
Olofsson (2008). “CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice,” Circulation, 117(10):1292-1301.
[cited by applicant]
Palma et al., (2004). “CD137 and CD137 Ligand Constitutively Coexpressed on Human T and B Leukemia Cells Signal Proliferation and Survival,” International Journal of Cancer, 108:390-398.
[cited by applicant]
Paul, (1993). “Chapter 9: Structure and Function of Immunoglobulins,” Fundamental Immunology, 3rd Edition, pp. 292-295.
[cited by applicant]
Peters et al. (2012). “Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability,” J Biol Chem. 287(29):24525-33.
[cited by applicant]
Ramagopal et al., (2017). “Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab,” Proc Natl Acad Sci USA 114(21): 4223-4232.
[cited by applicant]
Ribas et al., (2007). “Tremelimumab (CP-675, 206), a Cytotoxic T 1-61 Lymphocyte-Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer,” The Oncologist, 12:873-883.
[cited by applicant]
Schwartz et al., (2001). “Structural basis for co-stimulation by the human CTLA-4/B7-2 complex,” Nature 410(6828): 604-608.
[cited by applicant]
Seaman 2007. “Genes that distinguish physiological and pathological angiogenesis,” Cancer Cell, 11(6): 539-554.
[cited by applicant]
Segal et al., (2018). “Phase | Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer,” Clinical Cancer Research, 24:1816-1823.
[cited by applicant]
Shao et al., (2011). “CD137 Ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction,” J. Leukoc. Biol., 89: 21-29.
[cited by applicant]
Shao, Z. et al. (2015). “Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation,” J. Leukocyte Biol., 97:909-919.
[cited by applicant]
Sharma et al., (2019; epub 2018). “Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers,” Clin. Cancer Res., 25:1233-1238.
[cited by applicant]
Shi et al., (2006). “Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment,” Anticancer Res., 26(5A):3445-53.
[cited by applicant]
Stamper et al., (2001). “Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses,” Nature 410(6828): 608-611.
[cited by applicant]
Tian et al. (2015). “In-depth analysis of subclass-specific conformational preferences of IgG antibodies,” IUCrJ. 2(Pt 1):9-18.
[cited by applicant]
Tolcher et al., (2017). “Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumor,” Clin Cancer Res., 23(18):5349-5357.
[cited by applicant]
Tolcher et al., (2019). “A phase 1, first-in-human, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced ormetastatic solid tumors and/or relapsed/refractory non-Hodgki…
[cited by applicant]
Vajdos et al., (2002). “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis,” Journal of Molecular Biology, 320(2):415-28.
[cited by applicant]
Vinay et al., (2006). “Dual immunoregulatory pathways of 4-1BB signaling,” J Mol Med, 84(9):726-736.
[cited by applicant]
Wang et al., (2009). “Immune regulation by 4-1BB and 4-1BBL: complexities and challenges,” Immunological Reviews, 229(1):192-215.
[cited by applicant]
Wei et al. (2013). “Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin,” PLoS One. 8(12):1-11.
[cited by applicant]
Xiang, (1999). “Expression of Co-Stimulatory 4-1bb Ligand Induces Significant Tumor Regression and Protective Immunity,” Cancer Biother. Radiopharm., 14(5):353-61.
[cited by applicant]
Xiao et al., (2007). “Soluble PD-1 facilitates 4-IBBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo,” Clin Cancer Res., 13(6):1823-30.
[cited by applicant]
Xu et al., (2012). “Preparation and characterization of a chimeric anti-human CTLA-4 monoclonal antibody,” Current Immunology, 5(32):359-364. English Abstract Only.
[cited by applicant]
Yang et al., (1997). “Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages,” Cancer Res 57(18):4…
[cited by applicant]
Ye et al., (2020). “CD137, an attractive candidate for the immunotherapy of lung cancer,” Cancer Science, 111:1461-1467.
[cited by applicant]
Yi et al., (2009). “Location of extracellular cysteine-rich domains of 4-1BB binding to murine 4-1BB ligand and analysis of its possible structure,” Chin. J. Microbiol. Immunol. 4(29):343-344. Abstract Only.
[cited by applicant]
Yonezawa et al., (2015) “Boosting Cancer Immunotherapy with 1-3, 6-33 Anti-CD137 Antibody Therapy,” Clinical Cancer Research. 14(21):3113-3120.
[cited by applicant]
Zhang et al., (2020). “Phase 1, dose-escalation study of ADG106, a fully human anti-CD 137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma,” Journal of Clinical Onc…
[cited by applicant]
Bartkowiak et al., (2015). “4-1 BB agonists: multi-potent potentiators of tumor immunity,” Front. Oncol., 5:117, 16 pages.
[cited by applicant]
Chen et al., (1995). “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” EMBO J., 14(12):2784-2794.
[cited by applicant]
ClinicalTrials.gov, (2017). “T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer, NCT03318900,” Available online at <https://clinicaltrials.gov/ct2/show/NCT03318900?term=NCT03…
[cited by applicant]
Guillerey et al., (2016). “Abstract B155: Anti-CD137 mAb therapy of multiple myeloma,” Cancer Immunol Res., 4(1_Supplement):B155, 2 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority mailed Sep. 24, 2021, issued for PCT/US2021/038718, filed Jun. 23, 2021, 12 pages.
[cited by applicant]
Kranz et al., (1981). “Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies,” PNAS USA, 78(9):5807-5811.
[cited by applicant]
Kroon et al., (2016). “Concomitant targeting of programmed death-1 (PD-1) and CD 137 improves the efficacy ofimmunotherapy in a mouse model of human BRAFV600-mutant melanoma,” Cancer Immunology, Imunotherapy, 65:753-763.
[cited by applicant]
Lamminmaki et al., (2001). “Crystal structure of a recombinant anti-estradiol Fab fragment in complex with 17B-estradiol,” J. Biol. Chem., 276:36687-36694.
[cited by applicant]
Lin et al., (2011). “Improved affinity of a chicken single-chain antibody to avian infectious bronchitis virus by site-directed mutagenesis of complementarity-determining region H3,” African Journal of Biotechnology, 10…
[cited by applicant]
Liu et al., (2006). “Inhibition of murine syngeneic graft versus host disease by blockade of CD137/CD137L signaling pathway with anti-CD137L mAb,” Chinese Journal of Immunology, 22(7):619-622. Abstract Only.
[cited by applicant]
Mariuzza, (1987). “The Structural Basis of Antigen-Antibody Recognition,” Annu. Rev. Biophys. Biophys. Chem., 16:139-159.
[cited by applicant]
McCarthy et al., (2001). “Altering the fine specificity of an anti-Legionella single chain antibody by a single amino acid insertion,” J. Immunol. Methods, 251(1-2):137-149.
[cited by applicant]
Nezlin, (1970). “The Structure of Antibodies,” Biochemistry of Antibodies, p. 160, 4 pages.
[cited by applicant]
Quetglas et al., (2012). “Immunotherapeutic Synergy Between AntiCD137 mAb and Intratumoral Administration of a Cytopathic Semliki Forest Virus Encoding IL-12,” Molecular Therapy, 20(9):1664-1675.
[cited by applicant]
Sela-Culan et al., (2013). “The structural basis of antibody-antigen recognition,” Front. Immunol. 4:302, 13 pages.
[cited by applicant]
Senthilkumar et al., (2009). “CD137L- and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation,” Immunobiology, 214(2):153-61. Abstract Only.
[cited by applicant]
Won, (2010). “The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily,” J Biol Chem., 285(12):9202-10.
[cited by applicant]
Zhang et al., (2018). “Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity,” Nature Communications, 9(6):1-15.
[cited by applicant]
Abhinandan et al., (2008). “Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains,” Mol Immunol, 45:3832-3839, 11 pages.
[cited by applicant]
Adolf-Bryfogle et al., (2015). “PylgClassify: a database of antibody CDR structural classifications,” Nucleic Acids Res, 43:D432-D438.
[cited by applicant]
Al-Lazikani et al., (1997). “Standard conformations for the canonical structures of immunoglobulins,” J Mol. Biol., 273:927-948.
[cited by applicant]
Camacho et al., (2004). “Abstract 2505: Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies,” J Clin Oncology, 22(14_suppl), 3 pages.
[cited by applicant]
Chan et al., (2009). “Epitope mapping of a chimeric CD137 mAb: a necessary step for assessing the biologic relevance of non-human primate models,” Journal of Molecular Recognition, 22(3):242-249.
[cited by applicant]
Chen et al., (1999). “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen”, J. Mol. Biol., 293:865-881.
[cited by applicant]
Chester et al., (2018). “Immunotherapy targeting 4-1 BB_ mechanistic rationale, clinical results, and future strategies,” Blood, 131 (a):49-57.
[cited by applicant]
Chothia et al., (1987). “Canonical structures for the hypervariable regions of immunoglobulins,” J. Mol. Biol., 196:901-917.
[cited by applicant]
Chu et al., (2019). “An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer,” International Journal of Molecular Sciences, 20(8):1822, 17 pages.
[cited by applicant]
Creative-Diagnostics, (2022). “4-1 BB/4-1 Bbl Signaling Pathway,” available online at <https://www.creative-diagnostics.com/4-1 bb-4-1 bbl-signaling-pathway.htm>, 5 pages.
[cited by applicant]
Dimberg et al., (2006). “Expression of CD137 and CD137 ligand in colorectal cancer patients,” Oncol. Rep., 15(5):1197-1200.
[cited by applicant]
Ehrenmann et al., (2010). “IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF,” Nucleic Acids Res., 38:D301-D307.
[cited by applicant]
Fukunaga et al., (2018). “Improvement of antibody affinity by introduction of basic amino acid residues into the framework region,” Biochem. Biophys. Rep., 15:81-85.
[cited by applicant]
GenBank, (2023). Accession No. NM_001561.6: “
[cited by applicant]
GenBank, (2023). Accession No. NP_001552.2: “tumor necrosis factor receptor superfamily member 9 precursor [
[cited by applicant]
GenBank, (2020). Accession No. NM_001267706.1: “
[cited by applicant]
GenBank, (2023). Accession No. NM_001145966.2: “
[cited by applicant]
Gerngross, (2004). “Advances in the Production of Human Therapeutic Proteins in Yeasts and Filamentous Fungi,” Nat. Biotech., 22:1409-1414.
[cited by applicant]
Graham et al., (1977). “Characteristics of a Human Cell Line Transformed by DNA From Human Adenovirus Type 5,” J. Gen Virol., 36:59-72.
[cited by applicant]
Guillerey et al., (2016). “Abstract 764: Therapeutic potential anti-CD137 mAbs in multiple myeloma,” European Journal of Immunology. 46 (Suppl.1):1005-1006.
[cited by applicant]
Honegger et al., (2001).“Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” Mol Biol., 309:657-670.
[cited by applicant]
Kabat et al., (1977). “Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combin…
[cited by applicant]
Kamijo et al., (2017). “Abstract 522: Blocking CD137-CD137L interactions inhibits proliferation and survival of cutaneous T-cell lymphoma cells via hampering several signaling pathways,” J. Invest. Dermatol., 137(10)Sup…
[cited by applicant]
Kim et al., (2002). “Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes,” Immunology, 107:472-479.
[cited by applicant]
Kohler et al., (1975). “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, 256:495-7.
[cited by applicant]
Lefranc et al., (2003). “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev. Comp. Imunnol., 27:55-77.
[cited by applicant]
Lindbom et al., (2005). “PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM,” Comput Methods Programs Biomed., 79(3):241-57. Abstract Only.
[cited by applicant]
Masu et al., (2018). “Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 ex…
[cited by applicant]
Mather et al., (1982). “Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium,” Annals N.Y. Acad. Sci., 383:44-68.
[cited by applicant]
Mather, (1980). “Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines,” Biol. Reprod., 23:243-251.
[cited by applicant]
Mokyr et al., (1998). “Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice,” Cancer Res, 58:5301-5304.
[cited by applicant]
Segal, (2016). “Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody,” Clin. Cane. Res., 23(8):1929-1936.
[cited by applicant]
Sharma et al., (2020). “Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy,” Nature Communications, 11:661, 11 pages.
[cited by applicant]
Theze et al., (1996). “Interleukin 2 and its receptors: recent advances and new immunological functions,” Immunol. Today, 17(10):481-486. Abstract Only.
[cited by applicant]
Zapata et al., (2018). “CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs,” Frontiers in Immunology, 9:2618, 12 pages.
[cited by applicant]
Chacon et al., (2016). “The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy,” Vaccines, 4(4):43, 28 pages.
[cited by applicant]
Elpek et al., (2007). “Ex Vivo Expansion of CD4+CD25+FoxP3+ T Regulatory Cells Based on Synergy between IL-2 and 4-1BB Signaling,” J Immunol, 179(11):7295-7304.
[cited by applicant]
European Search Report received for European Patent Application No. 21828391.9 mailed on Sep. 18, 2024, 16 pages.
[cited by applicant]
Extended European Search Report and Opinion for European Patent Application No. 21803953.5, mailed on Jul. 17, 2024, 19 pages.
[cited by applicant]
Grivas et al., (2011). “Immunotherapy of Kidney Cancer,” Curr. Clin. Pharmacol., 6(3):151-163.
[cited by applicant]
International Search Report and Written Opinion received for International Patent Application No. PCT/CN2022/079475 mailed on Dec. 2, 2022, 13 pages.
[cited by applicant]
International Search Report and Written Opinion received for International Patent Application No. PCT/CN2023/079843 mailed on Apr. 12, 2023, 8 pages.
[cited by applicant]
Li et al., (2006). “Construction and identification of phage display system for human CD137 extracellular domain,” Chinese Journal of Immunology, 4:294-298. English abstract only. 2 pages.
[cited by applicant]
Partial European Search Report received for European Patent Application No. 21828391.9 mailed on Jun. 28, 2024, 21 pages.
[cited by applicant]
Unpublished U.S. Appl. No. 18/842,313, filed Mar. 6, 2023, titled “Anti- CD137 Antibodies and Methods of Making and Using the Same,” (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii)).
[cited by applicant]
Andria et al., (1990). “Diverse VH and VL genes are used to produce antibodies against a defined protein epitope,” J. Immunol., 144:2614-2619.
[cited by applicant]
ClinicalTrials.gov, (2018). “Study Details; Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma, NCT03707093,” available online at <https://www.clinicaltrials.gov/study/NCT…
[cited by applicant]
Herold et al., (2017). “Determinants of the assembly and function of antibody variable domains,” Scientific Reports, 7:12276, 17 pages.
[cited by applicant]
Partial European Search Report and Opinion for European Patent Application No. 21803953.5, mailed on Apr. 26, 2024, 23 pages.
[cited by applicant]
Vinay et al., (2015). “Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies,” Expert Opinion on Therapeutic Targets, 20:361-373. Abstract Only.
[cited by applicant]
Chichili et al., (2013). “Linkers in the structural biology of protein-protein interactions,” Prot. Sci., 22:153-167.
[cited by applicant]
Desnoyers et al., (2013). “Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index,” Sci. Transl. Med., 5(207):e144, 25 pages.
[cited by applicant]
Zhou et al., (2019). “Is protein context responsible for peptide-mediated interactions,” Mol. Omics, 15:280-295.
[cited by applicant]